» Media

Media

PRESENTATION OF INTERIM REPORT JANUARY – JUNE 2024

August 28, 2024

Presenter:
Martin Åmark, CEO

Anette Lindqvist, CFO

Press Conference Valorum 2024

May 13, 2024

Presenter:
Martin Åmark, CEO

Anette Lindqvist, CFO

Article Biostock, March 2024

Biostock

Presentation at Stora Aktiedagarna

Mars, 2024

Presenter:
Siavash Bashiri, COO & Head of Biosimilars

Xbrane Biopharma presents at the following events:

Stora aktiedagen 5 mars 2024

Swiss Nordic Bio 7 mars 2024

Biostock Health and Wealth 11-15 mars 2024 Health and Wealth – BioStock

NYHETSBYRÅN DIREKT'S INTERVIEW WITH CEO MARTIN ÅMARK regarding planned emission, FEBRUARY 2024

Nyhetsbyrån Direkt

Xbrane Letter to shareholders, february 2024

Letter to shareholders

Interview Life Science Sweden, December 2023

CTO David Vikström is interviewed about the art of building a biological drug

Life Science Sweden

Interview Di TV, November 2023

CEO Martin Åmark comments on the Q3 2023 quarterly reportLife Science Sweden November 2023

Dagens Indsustri

PRESENTATION OF INTERIM REPORT JANUARY – SEPTEMBER 2023

November 30, 2023

Presenter:
Martin Åmark, CEO

Anette Lindqvist, CFO

INTERVIEW WITH CEO MARTIN ÅMARK

October 17, 2023

PRESENTATION OF INTERIM REPORT JANUARY – JUNE 2023

August 29, 2023

Presenter:
Martin Åmark, CEO

Anette Lindqvist, CFO

Press conference

July, 2023

Presenter:
Martin Åmark, CEO

Presentation at ABGSC life Science Summit May 2023

May, 2023

Presenter:
Martin Åmark, CEO

Presentation at Redeye Life Science Day 2022

November, 2022

Presenter:
Martin Åmark, CEO

Q&A at Redeye Life Science Day 2022

November, 2022

Presenter:
Martin Åmark, CEO

Presentation at Erik Penser Bank HealthCare Day

February 24, 2022

Presenter:
Martin Åmark, CEO

Article Patent and Registration Office, 2021

Xbrane - "Our innovations and patents will provide more affordable and good medicines"

Read article PRV

Press conference, two new biosimilar canditates

December 14, 2021

Presenter:
Martin Åmark, CEO

Siavash Bashiri, COO

Exciting high risk share

ANALYSIS Xbrane Biopharma is an exceptionally promising hope company. The business world sees a long-term buying situation, but the risk is high.

Read the article